Gabapentin Does Not Effectively Reduce Methamphetamine Cravings
Based on the highest quality evidence, gabapentin should not be used to treat methamphetamine dependence or reduce cravings, as multiple well-designed placebo-controlled trials have failed to demonstrate efficacy.
Evidence Against Gabapentin for Methamphetamine
The FDA-approved indications for gabapentin are limited to postherpetic neuralgia and epilepsy 1. There is no FDA approval or guideline support for using gabapentin in stimulant dependence.
The 2013 American Family Physician guideline explicitly states that "no pharmacologic treatment for stimulant (e.g., cocaine, methamphetamine) dependence can be recommended for use in the primary care setting" and emphasizes that behavioral therapies are the only treatments with demonstrated effectiveness 2.
Clinical Trial Evidence Shows No Benefit
The research evidence consistently demonstrates gabapentin's ineffectiveness for methamphetamine:
A 2012 double-blind, placebo-controlled trial (n=120) evaluating the PROMETA protocol (flumazenil + gabapentin + hydroxyzine) found no statistically significant differences in urine drug tests, craving reduction, or treatment retention compared to placebo 3.
A 2006 randomized controlled trial (n=88) directly comparing gabapentin 800mg TID versus placebo found no statistically significant main effects in reducing methamphetamine use 4. Notably, this same study found a potential small effect for baclofen (a different GABAergic medication) in adherent patients, but not for gabapentin.
A 2019 systematic review concluded that "no significant benefit of gabapentin has been conclusively observed in the treatment of cocaine and amphetamine abuse" 5.
One Contradictory Study Has Methodological Concerns
A single 2011 study (n=30) reported reduced cravings with flumazenil plus gabapentin 6. However, this finding:
- Has not been replicated in larger, more rigorous trials
- Was contradicted by the 2012 PROMETA trial using the same medication combination 3
- Used a combination therapy, making it impossible to isolate gabapentin's effect
Important Safety Considerations
If gabapentin is being considered despite lack of efficacy evidence, be aware of significant risks:
Abuse potential: Gabapentin itself has documented misuse potential, particularly in patients with substance use disorders 1, 7. Multiple states have reclassified it as a Schedule V controlled substance due to abuse concerns.
Respiratory depression risk: When combined with opioids (common in polysubstance users), gabapentin causes additive/synergistic respiratory depression and increases overdose risk 8.
Withdrawal symptoms: Abrupt discontinuation after prolonged use can cause agitation, disorientation, and confusion 1.
Recommended Approach
Refer patients with methamphetamine dependence for evidence-based behavioral therapies 2. These include:
- Cognitive-behavioral therapy
- Contingency management
- Matrix Model
- Motivational interviewing
Do not prescribe gabapentin for methamphetamine cravings, as it lacks efficacy and introduces unnecessary risks in a vulnerable population already prone to polysubstance abuse.